Lv3
400 积分 2026-04-03 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Molecular Profiling across 80,000 Patients with Lung Cancer
1个月前
已完结
Immune checkpoint inhibitors in melanoma
1个月前
已完结
Endocrine toxicities of immune checkpoint inhibitors
1个月前
已完结
The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function
1个月前
已完结
Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors
1个月前
已完结
Role of oxygen sensing and hypoxia-inducible factors in orchestrating innate immune responses
1个月前
已完结
How oxygenation shapes immune responses: emerging roles for physioxia and pathological hypoxia
1个月前
已完结
Immune-checkpoint inhibitors: long-term implications of toxicity
1个月前
已完结
皖公网安备34019202002308
